VYNE reports Q3 net loss $7.3M; cash $32.7M; strategic review ongoing

VYNE Therapeutics Inc.

Net loss $7.3M ($0.17 per share) vs $12.2M ($0.29) in Q3 2024; revenue $0.2M from Finacea royalty.
Cash, cash equivalents and marketable securities $32.7M as of Sep 30, 2025; runway into first half 2027.
FDA partial clinical hold on VYN202 for male subjects; 12-week dog tox study ongoing to resolve.
Phase 2b repibresib gel for vitiligo failed primary endpoint F-VASI50; trial being terminated.
Board initiated strategic review in Aug 2025; evaluating partnerships, M&A, asset sales; LifeSci Capital engaged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.